AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11179277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine
Number of subjects: 22
Study 11179277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral homocysteine
Number of subjects: 22
Study 11179277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for methionine)
Number of subjects: 22
Study 11179277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for homocysteine)
Number of subjects: 22
Study 9425678 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying target letters in multiletter strings with different interletter steps
Number of subjects: 0
Study 9425678 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying terminal letters first
Number of subjects: 0
Study 8303206 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated wheat fibre (11 grams of Fiberform)
Number of subjects: 73
Study 8303206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 2963746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (300 mg/day) medroxyprogesterone acetate
Number of subjects: 124
Study 2963746 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (1000 mg/day) medroxyprogesterone acetate
Number of subjects: 124
Study 1267035 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana
Number of subjects: 10
Study 1267035 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana
Number of subjects: 10
Study 31427864 — intervention group
Group type: EXPERIMENTAL
Intervention: Living high-training low (LHTL)
Number of subjects: 24
Study 31427864 — intervention group
Group type: COMPARATOR
Intervention: Living low-training low (LLTL)
Number of subjects: 24
Study 28545189 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Triple Therapy (MTT): 20 mg omeprazole t.i.d., 500 mg amoxicillin t.i.d., and 500 mg clarithromycin b.i.d. for 14 days
Number of subjects: 170
Study 28545189 — intervention group
Group type: COMPARATOR
Intervention: Standard Triple Therapy (STT): 20 mg omeprazole b.i.d., 1000 mg amoxicillin b.i.d., and 500 mg clarithromycin b.i.d. for 14 days
Number of subjects: 170
Study 26179654 — intervention group
Group type: EXPERIMENTAL
Intervention: Human footprint (HFP)
Number of subjects: 0
Study 26179654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pteropus bat distribution
Number of subjects: 0
Study 26179654 — intervention group
Group type: COMPARATOR
Intervention: Vegetation cover
Number of subjects: 0
Study 23643313 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaural galvanic vestibular stimulation (GVS) with 1 mA direct current for 3 seconds
Number of subjects: 32
Study 23643313 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (no stimulation)
Number of subjects: 32
Study 20440106 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate counting programme (CCP)
Number of subjects: 56
Study 20440106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CCP)
Number of subjects: 56
Study 19273701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and best supportive care (BSC)
Number of subjects: 572
Study 19273701 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 572
Study 19273701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab in wild-type KRAS patients
Number of subjects: 572
Study 19273701 — intervention group
Group type: COMPARATOR
Intervention: BSC alone in wild-type KRAS patients
Number of subjects: 572
Study 17878149 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg yearly intravenous infusion)
Number of subjects: 2127
Study 17878149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 14742396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballpen needle (B)
Number of subjects: 700
Study 14742396 — intervention group
Group type: COMPARATOR
Intervention: Sprotte needle (S)
Number of subjects: 700
Study 11167370 — intervention group
Group type: COMPARATOR
Intervention: Freshly squeezed apple juice
Number of subjects: 65
Study 11167370 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly grated apple
Number of subjects: 65
Study 11167370 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried apple powder
Number of subjects: 65
Study 9129487 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (1.4 g/MJ)
Number of subjects: 59
Study 9129487 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium diet
Number of subjects: 59
Study 9129487 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran (control)
Number of subjects: 59
Study 7708414 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine injected 35 min before incision
Number of subjects: 42
Study 7708414 — intervention group
Group type: COMPARATOR
Intervention: Epidural normal saline injected 37 min before incision
Number of subjects: 42
Study 2885462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone for 7 days added to antibiotic regimen
Number of subjects: 10
Study 2885462 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy alone
Number of subjects: 10
Study 30246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants with a temporary resin fixed partial denture
Number of subjects: 26
Study 30246186 — intervention group
Group type: COMPARATOR
Intervention: Conventionally loaded implants with definitive multi-unit abutments
Number of subjects: 26
Study 30246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immediately loaded and conventionally loaded)
Number of subjects: 26
Study 26949133 — intervention group
Group type: EXPERIMENTAL
Intervention: PACK‐CXL
Number of subjects: 30
Study 26949133 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment alone)
Number of subjects: 30
Study 26949133 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 26201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supervised group sessions of progressive balance training for two years, supplemented by individually prescribed home exercises
Number of subjects: 706
Study 26201510 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 706
Study 26201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supervised group sessions of progressive balance training for two years
Number of subjects: 706
Study 23918953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cancer recovery (MBCR)
Number of subjects: 271
Study 23918953 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SET)
Number of subjects: 271
Study 23918953 — intervention group
Group type: COMPARATOR
Intervention: 1-day stress management control
Number of subjects: 271
Study 21916739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to questions about life events (stressful events and sexual violation)
Number of subjects: 219
Study 21916739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to questions about life events (other conditions)
Number of subjects: 219
Study 21916739 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exposure to trauma-related questions)
Number of subjects: 219
Study 18938022 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries Check Blue (CCB)
Number of subjects: 0
Study 18938022 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries Check (CC)
Number of subjects: 0
Study 18938022 — intervention group
Group type: COMPARATOR
Intervention: Caries Detector (CD)
Number of subjects: 0
Study 16675163 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach Case Management (OCM) for 6 weeks, designed to motivate and coach patients to re-enter treatment.
Number of subjects: 128
Study 16675163 — intervention group
Group type: COMPARATOR
Intervention: Passive Referral (PR) for drug treatment, n=52.
Number of subjects: 128
Study 16675163 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach Case Management (OCM) for 6 weeks.
Number of subjects: 128
Study 15579612 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 124
Study 15579612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 124
Study 15579612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 11760845 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with high percent body fat
Number of subjects: 239
Study 11760845 — intervention group
Group type: COMPARATOR
Intervention: Children born preterm
Number of subjects: 239
Study 11760845 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with varying percent body fat
Number of subjects: 239
Study 11760845 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with varying age
Number of subjects: 239
Study 9304342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidumbacterin forte
Number of subjects: 0
Study 8292689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 28
Study 8292689 — intervention group
Group type: COMPARATOR
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 28
Study 8292689 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 28
Study 8292689 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 28
Study 8292689 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 28
Study 8292689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasion-inion measurement
Number of subjects: 28
Study 3729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 0.1 mg/kg
Number of subjects: 12
Study 3729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 5 micrograms/kg
Number of subjects: 12
Study 3729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 2.0 mg/kg
Number of subjects: 12
Study 3729666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31643142 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health nurse in the treating team (in addition to case manager and doctor) for a 12-week period
Number of subjects: 0
Study 31643142 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (case manager and doctor)
Number of subjects: 0
Study 29105893 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional meal (potato-cheese cream followed by vanilla cream)
Number of subjects: 22
Study 29105893 — intervention group
Group type: COMPARATOR
Intervention: Unconventional meal (mixture of both creams)
Number of subjects: 22
Study 26547590 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant pulmonary function tests (iPFTs)
Number of subjects: 73
Study 26547590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean baseline FEV0.5, FEF75 and FRC z-scores
Number of subjects: 73
Study 24573661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil (EVOO)
Number of subjects: 3541
Study 24573661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 3541
Study 24573661 — intervention group
Group type: COMPARATOR
Intervention: Control diet (advice on a low-fat diet)
Number of subjects: 3541
Study 22412041 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 483
Study 22412041 — intervention group
Group type: COMPARATOR
Intervention: Letrozole + Zoledronic acid
Number of subjects: 483
Study 20798425 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofeedback-based teletreatment for 4 weeks
Number of subjects: 71
Study 20798425 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 71
Study 20798425 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofeedback-based teletreatment
Number of subjects: 71
Study 18072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10 mg/d
Number of subjects: 1434
Study 18072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 1434
Study 18072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 1434
Study 18072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 1434
Study 18072873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1434
Study 18072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene and Raloxifene
Number of subjects: 1434
Study 16794892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + > 65% N(2)O (Phase A)
Number of subjects: 80
Study 16794892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + > 65% N(2)O with reduced sevoflurane (Phase B)
Number of subjects: 80
Study 16794892 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Control in Phase A)
Number of subjects: 80
Study 16794892 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Control in Phase B)
Number of subjects: 80
Study 12796576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg oxandrolone twice a day (n = 14)
Number of subjects: 32
Study 12796576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 32
Study 12796576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg oxandrolone
Number of subjects: 32
Study 12634875 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker therapy (bisoprolol, carvedilol, metoprolol)
Number of subjects: 0
Study 12634875 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor therapy
Number of subjects: 0
Study 9033701 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual inflating long balloon prototype cannula (group I)
Number of subjects: 52
Study 9033701 — intervention group
Group type: COMPARATOR
Intervention: Manual inflating short balloon cannula (group II)
Number of subjects: 52
Study 1736733 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm NO2
Number of subjects: 40
Study 1736733 — intervention group
Group type: COMPARATOR
Intervention: Purified air (control)
Number of subjects: 40
Study 1736733 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of COPD and elderly normal subjects
Number of subjects: 40
Study 6476789 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dose of pyridoxine hydrochloride
Number of subjects: 2
Study 6476789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31246224 — intervention group
Group type: EXPERIMENTAL
Intervention: Default order option in the electronic medical record
Number of subjects: 0
Study 31246224 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (no default order)
Number of subjects: 0
Study 30379814 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of pentamidine isethionate (PI) 7 mg/kg
Number of subjects: 159
Study 30379814 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of pentamidine isethionate (PI) 7 mg/kg
Number of subjects: 159
Study 30379814 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of pentamidine isethionate (PI) 7 mg/kg
Number of subjects: 159
Study 27075333 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered intervention consisting of a decision aid for knee OA and motivational interviewing
Number of subjects: 493
Study 27075333 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet about OA that did not mention joint replacement (Control)
Number of subjects: 493
Study 25062131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-assisted epithelial debridement
Number of subjects: 88
Study 25062131 — intervention group
Group type: COMPARATOR
Intervention: Mechanical epithelial debridement
Number of subjects: 88
Study 25062131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 23514685 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort control syringe (CCS)
Number of subjects: 50
Study 23514685 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection technique
Number of subjects: 50
Study 20654755 — intervention group
Group type: EXPERIMENTAL
Intervention: EE30/LNG150
Number of subjects: 97
Study 20654755 — intervention group
Group type: EXPERIMENTAL
Intervention: EE20/LNG100
Number of subjects: 97
Study 17689509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary BH4 (250 microg/min & 500 microg/min) co-administered with acetylcholine (Ach, 10(‐7) & 10(‐6) M)
Number of subjects: 57
Study 17689509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary BH4 (500 microg/min) co-administered with acetylcholine (Ach, 10(‐7) & 10(‐6) M)
Number of subjects: 57
Study 17689509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BH4 treatment)
Number of subjects: 57
Study 16248952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor vaccine (3 vaccinations at 2-week intervals, consisting of formalin-fixed HCC tissue fragments, biodegradable sustained-releasers of GM-CSF, IL-2, and an adjuvant)
Number of subjects: 80
Study 16248952 — intervention group
Group type: COMPARATOR
Intervention: Control group (received only the adjuvant)
Number of subjects: 80
Study 16248952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor vaccine
Number of subjects: 80
Study 11895628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of small amounts of allergenic foods
Number of subjects: 0
Study 11895628 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold doses for allergenic foods
Number of subjects: 0
Study 11895628 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept of threshold level
Number of subjects: 0
Study 10193870 — intervention group
Group type: EXPERIMENTAL
Intervention: New anthropometric prediction equation developed from stepwise regression analysis in the development group (n = 135) using weight, triceps skinfold, gender, ethnicity, and abdominal skinfold to estimate fat mass (FM) measured by DEXA.
Number of subjects: 202
Study 10193870 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 67) used for cross-validation of the new prediction equation.
Number of subjects: 202
Study 10193870 — intervention group
Group type: COMPARATOR
Intervention: Previously published equations of Slaughter et al and Goran et al.
Number of subjects: 202
Study 7766742 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg mane), Amoxycillin (500 mg t.d.s.), Metronidazole (400 mg t.d.s.) for 14 days
Number of subjects: 436
Study 7766742 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg mane), Amoxycillin (500 mg t.d.s.), Metronidazole (400 mg t.d.s.) for 7 days
Number of subjects: 436
Study 7766742 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg mane), Amoxycillin (500 mg t.d.s.) for 7 days and Metronidazole for 5 days
Number of subjects: 436
Study 7766742 — intervention group
Group type: COMPARATOR
Intervention: 14 days treatment
Number of subjects: 436
Study 2271374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 12
Study 2271374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7411316 — intervention group
Group type: EXPERIMENTAL
Intervention: Special stimulation for babies to enhance interaction
Number of subjects: 0
Study 7411316 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training for mothers to enhance responsiveness
Number of subjects: 0
Study 7411316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation for infants and training for mothers
Number of subjects: 0
Study 7411316 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital care (control group)
Number of subjects: 0
Study 31130153 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of alcohol problems (FHAP)
Number of subjects: 333
Study 31130153 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of depression (FHD)
Number of subjects: 333
Study 31494152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) 2.5h after breakfast
Number of subjects: 14
Study 31494152 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 14
Study 31494152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) 1h after breakfast
Number of subjects: 14
Study 31494152 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-State Exercise (SSE) 2.5h after breakfast
Number of subjects: 14
Study 31494152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) 1h and Steady-State Exercise (SSE) 1h
Number of subjects: 14
Study 31494152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) 1h and HIIE 2.5h
Number of subjects: 14
Study 28968735 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397
Study 28968735 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397
Study 28968735 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 397
Study 28968735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 26899778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg orally on days 1-21 every 28 days)
Number of subjects: 254
Study 26899778 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice monotherapy (rituximab, gemcitabine, fludarabine, chlorambucil, or cytarabine)
Number of subjects: 254
Study 26899778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 254
Study 26899778 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice
Number of subjects: 254
Study 25493978 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 1195
Study 25493978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study 21818628 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 28
Study 21818628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21818628 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 28
Study 19776140 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g prebiotics/d
Number of subjects: 10
Study 19776140 — intervention group
Group type: COMPARATOR
Intervention: 16 g dextrin maltose/d
Number of subjects: 10
Study 17309590 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth root planing (FMRP)
Number of subjects: 20